CY1119609T1 - Ταχειας διαλυτοποιησης σκευασμα σινακαλσετης - Google Patents

Ταχειας διαλυτοποιησης σκευασμα σινακαλσετης

Info

Publication number
CY1119609T1
CY1119609T1 CY20171101211T CY171101211T CY1119609T1 CY 1119609 T1 CY1119609 T1 CY 1119609T1 CY 20171101211 T CY20171101211 T CY 20171101211T CY 171101211 T CY171101211 T CY 171101211T CY 1119609 T1 CY1119609 T1 CY 1119609T1
Authority
CY
Cyprus
Prior art keywords
sinakalset
packaging
pharmaceutical composition
fast solution
present
Prior art date
Application number
CY20171101211T
Other languages
Greek (el)
English (en)
Inventor
Francisco J. Alvarez
Tzuchi R. Ju
Hung-Ren H. Lin
Glen Cary Lawrence
Original Assignee
Amgen Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34434844&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1119609(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Amgen Inc. filed Critical Amgen Inc.
Publication of CY1119609T1 publication Critical patent/CY1119609T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A61P5/20—Drugs for disorders of the endocrine system of the parathyroid hormones for decreasing, blocking or antagonising the activity of PTH

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CY20171101211T 2003-09-12 2017-11-20 Ταχειας διαλυτοποιησης σκευασμα σινακαλσετης CY1119609T1 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US50221903P 2003-09-12 2003-09-12
EP10014567A EP2316442A1 (en) 2003-09-12 2004-09-10 Rapid dissolution formulation of a calcium receptor-active compound
EP04781429.8A EP1663182B2 (en) 2003-09-12 2004-09-10 RAPID DISSOLUTION FORMULATION OF CINACALCET HCl

Publications (1)

Publication Number Publication Date
CY1119609T1 true CY1119609T1 (el) 2018-04-04

Family

ID=34434844

Family Applications (5)

Application Number Title Priority Date Filing Date
CY20171101211T CY1119609T1 (el) 2003-09-12 2017-11-20 Ταχειας διαλυτοποιησης σκευασμα σινακαλσετης
CY20191100682T CY1122259T1 (el) 2003-09-12 2019-06-28 Φαρμακοτεχνικη μορφη ταχειας διαλυτοποιησης η οποια περιλαμβανει σινακαλσετη hcl
CY20191100735T CY1121814T1 (el) 2003-09-12 2019-07-10 Φαρμακοτεχνικη μορφη ταχειας διαλυτοποιησης της σινακαλσετης hcl
CY20191100734T CY1121812T1 (el) 2003-09-12 2019-07-10 Φαρμακοτεχνικη μορφη ταχειας διαλυτοποιησης η οποια περιλαμβανει σινακαλσετη hcl
CY20191100767T CY1121820T1 (el) 2003-09-12 2019-07-18 Φαρμακοτεχνικη μορφη ταχειας διααυτοποιησης σινακαλσετης hcl

Family Applications After (4)

Application Number Title Priority Date Filing Date
CY20191100682T CY1122259T1 (el) 2003-09-12 2019-06-28 Φαρμακοτεχνικη μορφη ταχειας διαλυτοποιησης η οποια περιλαμβανει σινακαλσετη hcl
CY20191100735T CY1121814T1 (el) 2003-09-12 2019-07-10 Φαρμακοτεχνικη μορφη ταχειας διαλυτοποιησης της σινακαλσετης hcl
CY20191100734T CY1121812T1 (el) 2003-09-12 2019-07-10 Φαρμακοτεχνικη μορφη ταχειας διαλυτοποιησης η οποια περιλαμβανει σινακαλσετη hcl
CY20191100767T CY1121820T1 (el) 2003-09-12 2019-07-18 Φαρμακοτεχνικη μορφη ταχειας διααυτοποιησης σινακαλσετης hcl

Country Status (30)

Country Link
US (7) US7829595B2 (cg-RX-API-DMAC7.html)
EP (8) EP2821067B1 (cg-RX-API-DMAC7.html)
JP (3) JP5026077B2 (cg-RX-API-DMAC7.html)
KR (1) KR101332058B1 (cg-RX-API-DMAC7.html)
CN (1) CN1946382B (cg-RX-API-DMAC7.html)
AR (1) AR045637A1 (cg-RX-API-DMAC7.html)
AU (1) AU2004279318C1 (cg-RX-API-DMAC7.html)
BR (2) BR122018013029B1 (cg-RX-API-DMAC7.html)
CA (1) CA2536487C (cg-RX-API-DMAC7.html)
CY (5) CY1119609T1 (cg-RX-API-DMAC7.html)
DE (1) DE19164145T1 (cg-RX-API-DMAC7.html)
DK (6) DK3395338T3 (cg-RX-API-DMAC7.html)
EA (1) EA013425B1 (cg-RX-API-DMAC7.html)
ES (7) ES2735226T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20130114T4 (cg-RX-API-DMAC7.html)
HU (5) HUE045411T2 (cg-RX-API-DMAC7.html)
IL (1) IL173737A (cg-RX-API-DMAC7.html)
IS (1) IS3027B (cg-RX-API-DMAC7.html)
MX (1) MXPA06002616A (cg-RX-API-DMAC7.html)
MY (1) MY142046A (cg-RX-API-DMAC7.html)
NO (1) NO335739B1 (cg-RX-API-DMAC7.html)
NZ (1) NZ545498A (cg-RX-API-DMAC7.html)
PL (6) PL3395340T3 (cg-RX-API-DMAC7.html)
PT (6) PT3395338T (cg-RX-API-DMAC7.html)
SG (1) SG146608A1 (cg-RX-API-DMAC7.html)
SI (6) SI3395338T1 (cg-RX-API-DMAC7.html)
TR (4) TR201910180T4 (cg-RX-API-DMAC7.html)
TW (1) TWI344363B (cg-RX-API-DMAC7.html)
WO (1) WO2005034928A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA200602710B (cg-RX-API-DMAC7.html)

Families Citing this family (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2004279318C1 (en) 2003-09-12 2020-06-25 Amgen Inc. Rapid dissolution formulation of a calcium receptor-active compound
ME02799B (me) 2004-06-24 2018-01-20 Vertex Pharma Modulatori ATP-vezujućih kasetnih transportera
ATE443038T1 (de) * 2005-05-16 2009-10-15 Teva Pharma Verfahren zur herstellung von cinacalcet hydrochlorid
WO2006127941A2 (en) * 2005-05-23 2006-11-30 Teva Pharmaceutical Industries Ltd. Amorphous cinacalcet hydrochloride and preparation thereof
CA2606099A1 (en) * 2005-05-23 2006-11-30 Teva Pharmaceutical Industries Ltd. Processes for preparing cinacalcet hydrochloride crystal form i
WO2006126681A1 (ja) 2005-05-26 2006-11-30 Dainippon Sumitomo Pharma Co., Ltd. 医薬品組成物
JP5244597B2 (ja) * 2005-09-02 2013-07-24 アムジエン・インコーポレーテツド カルシリティック化合物またはカルシウム模倣性化合物を用いて腸液バランスを調節する方法
KR20080055990A (ko) * 2005-11-22 2008-06-19 테바 파마슈티컬 인더스트리즈 리미티드 시나칼셋 ＨＣｌ의 결정형 및 이의 제조 방법
CA2635581C (en) 2005-12-28 2017-02-28 Vertex Pharmaceuticals Incorporated Solid forms of n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide
ES2904546T3 (es) 2006-02-03 2022-04-05 Opko Renal Llc Tratamiento de la insuficiencia y deficiencia de vitamina D con 25-hidroxivitamina D2 y 25-hidroxivitamina D3
EP2001832A1 (en) * 2006-03-23 2008-12-17 Amgen Inc. Methods and compositions for making and using polymorphs of cinacalcet
EP1928817A1 (en) * 2006-04-27 2008-06-11 Teva Pharmaceutical Industries Ltd Process for the preparation of cinacalcet base
US7449603B2 (en) * 2006-04-27 2008-11-11 Teva Pharmaceutical Industries Ltd. Process for the preparation of cinacalcet base
SI2037936T1 (sl) 2006-06-21 2014-11-28 Opko Renal, Llc Postopek zdravljenja in prepreäśevanja sekundarnega hiperparatiroidizma
US20090258949A1 (en) * 2006-06-27 2009-10-15 Johannes Ludescher Amorphous form of cinacalcet
BRPI0715635A2 (pt) * 2006-09-01 2013-07-02 Teva Pharma compàsitos sàlidos de um composto de cÁlcio receptor-ativo
WO2008064202A2 (en) * 2006-11-20 2008-05-29 Dr. Reddy's Labortories, Ltd. Modified-release formulations of calcium receptor-active compounds
US20080146845A1 (en) * 2006-11-20 2008-06-19 Boaz Gome Process for preparing Cinacalcet
TWI573802B (zh) 2007-03-06 2017-03-11 安美基公司 變異之活動素受體多肽及其用途
WO2008122010A1 (en) * 2007-04-02 2008-10-09 Concert Pharmaceuticals, Inc. Pharmaceutical calcimimetics
CA2683628C (en) 2007-04-25 2018-03-06 Cytochroma Inc. Method of treating vitamin d insufficiency and deficiency
PT2148661E (pt) 2007-04-25 2013-03-06 Proventiv Therapeutics Llc Composições orais de libertação controlada compreendendo um composto de vitamina d e veículo ceroso
WO2009002427A2 (en) 2007-06-21 2008-12-31 Amgen Inc. Methods of synthesizing cinacalcet and salts thereof
WO2009025792A2 (en) * 2007-08-16 2009-02-26 Teva Pharmaceutical Industries Ltd. Crystalline forms cinacalcet fumarate and cinacalcet succinate and processes for preparation thereof
EP2300415A2 (en) * 2008-05-05 2011-03-30 Medichem, S.A. Process for controlling the particle size of a 3-(trifluoromethyl)phenyl¨-1-aminopropane derivative
US12458635B2 (en) 2008-08-13 2025-11-04 Vertex Pharmaceuticals Incorporated Pharmaceutical composition and administrations thereof
US20100074949A1 (en) * 2008-08-13 2010-03-25 William Rowe Pharmaceutical composition and administration thereof
US20100256184A1 (en) * 2008-08-13 2010-10-07 Vertex Pharmaceuticals Incorporated Pharmaceutical composition and administrations thereof
WO2010034497A2 (de) 2008-09-25 2010-04-01 Ratiopharm Gmbh Kompaktiertes cinacalcet
WO2010086129A1 (en) 2009-01-27 2010-08-05 Rathiopharm Gmbh Inclusion complex comprising cinacalcet and cyclodextrin
SI2408750T1 (sl) 2009-03-20 2015-11-30 Vertex Pharmaceuticals Incorporated Postopek za izdelavo modulatorjev cistično-fibroznega transmembranskega regulatorja prevodnosti
JP2012528086A (ja) 2009-05-27 2012-11-12 レオ ファーマ アクティーゼルスカブ 新規のカルシウム感知受容体調節化合物およびその医薬用途
CA2762130A1 (en) 2009-05-27 2010-12-02 Leo Pharma A/S Novel calcium sensing receptor modulating compounds and pharmaceutical use thereof
EP2314286A1 (de) 2009-10-21 2011-04-27 Ratiopharm GmbH Schmelzgranuliertes Cinacalcet
CN105796530A (zh) 2010-03-29 2016-07-27 赛特克罗公司 用于降低甲状旁腺水平的方法和组合物
CN103347517B (zh) 2010-08-11 2018-10-02 德雷克塞尔大学 治疗帕金森病中运动障碍的d3多巴胺受体激动剂
HUE049344T2 (hu) * 2010-11-23 2020-09-28 Amgen Inc Gyermekgyógyászati készítmény
JP2014508104A (ja) 2010-11-26 2014-04-03 レオ ファーマ アクティーゼルスカブ カルシウム感知受容体活性化合物
CN103228629A (zh) 2010-11-26 2013-07-31 利奥制药有限公司 作为CaSR活性化合物的被取代的环戊基-氮杂苯类
JP2014507375A (ja) 2010-11-26 2014-03-27 レオ ファーマ アクティーゼルスカブ カルシウム感知受容体活性化合物
JP2014508103A (ja) 2010-11-26 2014-04-03 レオ ファーマ アクティーゼルスカブ カルシウム感知受容体活性化合物
BR112014015003A2 (pt) * 2011-12-19 2019-09-24 Amgen Inc composição farmacêutica, método para tratar um cancer e método para reduzir o tamanho de uma massa tumoral
EP2804588B1 (en) 2012-01-17 2017-09-06 Zentiva Saglik Urunleri San. Ve Tic. A.S. Method for producing cinacalcet compositions for direct tableting
HK1203840A1 (en) 2012-02-27 2015-11-06 沃泰克斯药物股份有限公司 Pharmaceutical composition and administration thereof
CN102885792A (zh) * 2012-10-12 2013-01-23 华润赛科药业有限责任公司 盐酸西那卡塞的口服固体速释制剂
ES2547577T3 (es) * 2012-11-09 2015-10-07 K.H.S. Pharma Holding Gmbh Formulaciones de liberación inmediata de cinacalcet
US10835495B2 (en) 2012-11-14 2020-11-17 W. R. Grace & Co.-Conn. Compositions containing a biologically active material and a non-ordered inorganic oxide material and methods of making and using the same
US9895325B2 (en) 2012-12-21 2018-02-20 Synthon B.V. Tablet composition comprising cinacalcet hydrochloride
EA201591423A1 (ru) 2013-02-01 2016-01-29 Санта Мария Биотерапевтикс, Инк. Введение антитела к активину-а пациентам
KR101847947B1 (ko) 2013-03-15 2018-05-28 옵코 아이피 홀딩스 Ⅱ 인코포레이티드 안정화되고 변형된 비타민 ｄ 방출 제형
WO2014207691A1 (en) 2013-06-26 2014-12-31 Jubilant Life Sciences Limited Disintegrant free composition of cinacalcet
WO2015136329A1 (en) * 2014-03-14 2015-09-17 Abdi Ibrahim Ilac Sanayi Ve Ticaret Anonim Sirketi Pharmaceutical composition of cinacalcet
WO2015150944A1 (en) 2014-03-29 2015-10-08 Wockhardt Limited Solid oral pharmaceutical compositions comprising cinacalcet or a salt thereof
US10220047B2 (en) * 2014-08-07 2019-03-05 Opko Ireland Global Holdings, Ltd. Adjunctive therapy with 25-hydroxyvitamin D and articles therefor
JP6746569B2 (ja) 2014-10-07 2020-08-26 バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ 嚢胞性線維症膜貫通コンダクタンス制御因子のモジュレーターの共結晶
CN104721164B (zh) * 2015-03-25 2017-07-07 河北仁合益康药业有限公司 一种盐酸西那卡塞薄膜衣片组合物
UA129792C2 (uk) 2016-03-28 2025-08-06 Ейрджен Фарма Лтд. Способи лікування вітаміном d
CA3019508A1 (en) 2016-03-31 2017-10-05 Intercept Pharmaceuticals, Inc. Oral preparation having exceptional elutability
US11331283B2 (en) * 2017-08-16 2022-05-17 Unichem Laboratories Ltd Pharmaceutical compositions comprising cinacalcet hydrochloride and one or more binders
EP3773533A1 (en) 2018-03-30 2021-02-17 FTF Pharma Private Limited Liquid dosage forms of cinacalcet or salt thereof
US10920483B2 (en) 2018-10-25 2021-02-16 Mark Mutchnik Window seal for preventing water penetration
RU2750761C2 (ru) * 2019-09-17 2021-07-02 Общество с ограниченной ответственностью "АМЕДАРТ" Ядро таблетки, содержащей цинакальцета гидрохлорид
EP4110304A4 (en) * 2020-02-29 2024-06-05 Zevra Therapeutics, Inc. COMPOSITIONS COMPRISING METHYLPHENIDATE PRODRUGS, METHODS OF PREPARATION THEREOF AND METHODS OF USE
CN112546010A (zh) * 2020-12-02 2021-03-26 普莱赛思(天津)生命科技有限公司 一种肾病药物组合物及其制备方法

Family Cites Families (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4517179A (en) 1983-04-29 1985-05-14 Pennwalt Corporation Rapid dissolving, uniform drug compositions and their preparation
IL88150A0 (en) 1987-11-02 1989-06-30 Merck & Co Inc Pharmaceutical tablet compositions containing phthalizine acetic acid compounds
EP0357815A1 (de) 1988-09-06 1990-03-14 Siemens Aktiengesellschaft Schaltbare Konstantstromquelle mit I2L-Gattern
KR900701255A (ko) 1988-11-30 1990-12-01 스테이너 브이.캔스타드 서방성 딜티아젬 제제
NZ231897A (en) 1988-12-30 1992-09-25 Monsanto Co Dry water-soluble granular composition comprising glyphosate and a liquid surfactant
US5126145A (en) 1989-04-13 1992-06-30 Upsher Smith Laboratories Inc Controlled release tablet containing water soluble medicament
US4931286A (en) 1989-04-19 1990-06-05 Aqualon Company High gloss cellulose tablet coating
DD299322A5 (de) * 1989-09-21 1992-04-09 Maschinenfabrik Rieter Ag,Ch Verfahren und vorrichtung zur feinreinigung von textilfasern
US5011068A (en) * 1989-12-05 1991-04-30 Progressive Tool & Industries Co. Automotive body framing system
WO1995011221A1 (en) 1991-08-23 1995-04-27 Nps Pharmaceuticals, Inc. Calcium receptor-active arylalkyl amines
US6031003A (en) * 1991-08-23 2000-02-29 Nps Pharmaceuticals, Inc. Calcium receptor-active molecules
US6313146B1 (en) 1991-08-23 2001-11-06 Nps Pharmaceuticals, Inc. Calcium receptor-active molecules
US6011068A (en) 1991-08-23 2000-01-04 Nps Pharmaceuticals, Inc. Calcium receptor-active molecules
US6001884A (en) 1991-08-23 1999-12-14 Nps Pharmaceuticals, Inc. Calcium receptor-active molecules
ATE312347T1 (de) 1991-08-23 2005-12-15 Nps Pharma Inc Screening-verfahren für kalzium-rezeptor aktive verbindungen
US5162117A (en) 1991-11-22 1992-11-10 Schering Corporation Controlled release flutamide composition
DE69333527T2 (de) 1993-02-23 2005-06-16 Brigham & Women's Hospital, Inc., Boston Calciumrezeptoraktive moleküle
US6210714B1 (en) 1993-11-23 2001-04-03 Euro-Celtique S.A. Immediate release tablet cores of acetaminophen having sustained-release coating
UA41909C2 (uk) * 1994-07-22 2001-10-15 Елі Ліллі Енд Компані Використання комбінації сполук для інгібірування остеопорозу, фармацевтичний препарат
EP1275635A1 (en) * 1994-10-21 2003-01-15 Nps Pharmaceuticals, Inc. Calcium receptor-active compounds
GB9424766D0 (en) 1994-12-07 1995-02-08 Wellcome Found Pharmaceutical composition
GB9501127D0 (en) 1995-01-20 1995-03-08 Wellcome Found Tablet
DE19530575A1 (de) 1995-08-19 1997-02-20 Gruenenthal Gmbh Schnell zerfallende Arzneiform von Tramadol oder einem Tramadolsalz
DE69739388D1 (de) 1996-05-01 2009-06-10 Nps Pharma Inc Inorganische am Ionen-Rezeptor aktive Verbindungen
US5837292A (en) * 1996-07-03 1998-11-17 Yamanouchi Europe B.V. Granulate for the preparation of fast-disintegrating and fast-dissolving compositions containing a high amount of drug
US6362231B1 (en) 1996-07-08 2002-03-26 Nps Pharmaceuticals, Inc. Calcium receptor active compounds
DE19637082A1 (de) 1996-09-12 1998-03-19 Boehringer Mannheim Gmbh Schnellzerfallende Pellets
TW483881B (en) 1996-12-03 2002-04-21 Nps Pharma Inc Calcilytic compounds
IE970588A1 (en) 1997-08-01 2000-08-23 Elan Corp Plc Controlled release pharmaceutical compositions containing tiagabine
WO1999009458A1 (de) 1997-08-13 1999-02-25 OCé PRINTING SYSTEMS GMBH Druck- oder kopiergerätesystem zum performanceangepassten erstellen einer vorgegebenen blattfolge von monochrom und/oder farbig bedruckten einzelblättern
CA2322315C (en) 1998-03-06 2008-09-16 Eurand International S.P.A. Fast disintegrating tablets
US6525084B2 (en) 1998-07-23 2003-02-25 Novo Nordisk A/S Stable pharmaceutical formulation
JP2002527414A (ja) 1998-10-14 2002-08-27 オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド １，２−ジ置換シクロプロパン
AU775094B2 (en) 1998-11-23 2004-07-15 Monsanto Technology Llc Highly concentrated aqueous glyphosate compositions
UA74141C2 (uk) 1998-12-09 2005-11-15 Дж.Д. Сірл Енд Ко. Фармацевтична композиція на основі тонкоподрібненого еплеренону (варіанти), спосіб її одержання та спосіб лікування розладів, опосередкованих альдостероном (варіанти)
US6248363B1 (en) 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US6447809B1 (en) * 1999-05-11 2002-09-10 Metagenics, Inc. Composition for promoting healthy bone structure
US6733780B1 (en) 1999-10-19 2004-05-11 Genzyme Corporation Direct compression polymer tablet core
FR2800735B1 (fr) 1999-11-09 2002-02-01 Centre Nat Rech Scient Nouvelles aralkyle-1,2-diamines possedant une activite calcimimetique et leur mode de preparation
EP1239856A1 (en) 1999-12-22 2002-09-18 Pharmacia Corporation Sustained-release formulation of a cyclooxygenase-2 inhibitor
GB0001621D0 (en) * 2000-01-26 2000-03-15 Astrazeneca Ab Pharmaceutical compositions
WO2001078725A2 (en) 2000-04-13 2001-10-25 Synthon B.V. Modified release formulations containing a hypnotic agent
US6419954B1 (en) * 2000-05-19 2002-07-16 Yamanouchi Pharmaceutical Co., Ltd. Tablets and methods for modified release of hydrophilic and other active agents
FR2809396B1 (fr) 2000-05-24 2005-10-14 Centre Nat Rech Scient Nouvelles molecules possedant une activite calcimimetique et leur mode de preparation
US6656492B2 (en) * 2000-06-30 2003-12-02 Yamanouchi Pharmaceutical Co., Ltd. Quick disintegrating tablet in buccal cavity and manufacturing method thereof
WO2002024230A1 (en) 2000-09-22 2002-03-28 Takeda Chemical Industries, Ltd. Solid preparations
JP2002167327A (ja) * 2000-09-22 2002-06-11 Takeda Chem Ind Ltd 固形製剤
US7049283B2 (en) * 2000-12-06 2006-05-23 Novartis Ag Pharmaceutical compositions for the oral delivery of pharmacologically active agents
IN191028B (cg-RX-API-DMAC7.html) 2001-05-17 2003-09-13 Sun Pharmaceutical Ind Ltd
ES2284871T3 (es) 2001-06-22 2007-11-16 Pfizer Products Inc. Composiciones farmaceuticas que contienen una dispersion solida de farmaco poco soluble y un polimero potenciador de la solubilidad.
EP1321142A1 (en) 2001-12-21 2003-06-25 Novartis AG Solid pharmaceutical composition for oral administration of Tegaserod
WO2003086343A2 (en) 2002-04-05 2003-10-23 Cadila Healthcare Limited Fast disintegrating oral dosage forms
US20050147670A1 (en) * 2002-05-29 2005-07-07 Impax Laboratories Inc. Oral disintegrating dosage forms
WO2004030669A1 (en) 2002-09-30 2004-04-15 Schering Corporation Use of tricyclic amides for the treatment of disorders of calcium homeostasis
GB0230015D0 (en) 2002-12-23 2003-01-29 Novartis Ag Organic compounds
AU2004279318C1 (en) 2003-09-12 2020-06-25 Amgen Inc. Rapid dissolution formulation of a calcium receptor-active compound
PT1713489E (pt) 2004-08-23 2011-03-03 Teva Pharma Forma cristalina de ibandronato de sódio e processos para a sua preparação
NL1028867C2 (nl) 2005-04-26 2006-10-27 Xycarb Ceramics B V Inrichting voor het ondersteunen van een substraat alsmede een werkwijze voor het vervaardigen van een dergelijke inrichting.
US8922209B2 (en) 2008-03-11 2014-12-30 The University Of Western Ontario System and method for magnetic resonance imaging

Also Published As

Publication number Publication date
PL2821067T3 (pl) 2018-02-28
PT3395338T (pt) 2019-07-23
EP2821067A1 (en) 2015-01-07
NO20061640L (no) 2006-06-12
EP3578175B1 (en) 2022-11-30
WO2005034928A1 (en) 2005-04-21
DK3395339T3 (da) 2019-07-22
US20160338975A1 (en) 2016-11-24
NO335739B1 (no) 2015-02-02
SI1663182T2 (sl) 2020-02-28
CA2536487A1 (en) 2005-04-21
US7829595B2 (en) 2010-11-09
AR045637A1 (es) 2005-11-02
US20050147669A1 (en) 2005-07-07
KR20070017460A (ko) 2007-02-12
PL3260117T3 (pl) 2019-10-31
ES2401769T3 (es) 2013-04-24
TW200518743A (en) 2005-06-16
IS3027B (is) 2021-03-15
EP3260117B1 (en) 2019-04-17
KR101332058B1 (ko) 2013-11-22
MXPA06002616A (es) 2006-06-05
TWI344363B (en) 2011-07-01
US20200222340A1 (en) 2020-07-16
DK3395338T3 (da) 2019-07-22
DK2821067T3 (en) 2017-12-04
HRP20130114T1 (xx) 2013-03-31
EP1663182A1 (en) 2006-06-07
DK1663182T3 (da) 2013-04-15
SI1663182T1 (sl) 2013-05-31
ES2735226T3 (es) 2019-12-17
PT3260117T (pt) 2019-07-04
PL3395338T3 (pl) 2019-10-31
AU2004279318B2 (en) 2010-02-25
CY1121814T1 (el) 2020-07-31
MY142046A (en) 2010-08-30
IS8324A (is) 2006-02-23
ES2734057T3 (es) 2019-12-04
US20180243238A1 (en) 2018-08-30
EP2316442A1 (en) 2011-05-04
CN1946382A (zh) 2007-04-11
TR201910180T4 (tr) 2019-07-22
SI3395339T1 (sl) 2019-08-30
US9375405B2 (en) 2016-06-28
DE19164145T1 (de) 2021-04-29
JP2012197280A (ja) 2012-10-18
PL3395339T3 (pl) 2019-09-30
EP3395339B8 (en) 2019-12-11
EA200600566A1 (ru) 2006-08-25
PL1663182T3 (pl) 2013-06-28
SI3395338T1 (sl) 2019-08-30
DK3395340T3 (da) 2019-07-15
JP2007505108A (ja) 2007-03-08
AU2004279318C1 (en) 2020-06-25
ES2655435T3 (es) 2018-02-20
PT2821067T (pt) 2017-12-01
PL1663182T5 (pl) 2020-07-27
EP2821067B1 (en) 2017-10-25
JP5940120B2 (ja) 2016-06-29
HUE035596T2 (en) 2018-05-28
JP5849015B2 (ja) 2016-01-27
CY1121820T1 (el) 2020-07-31
ES2401769T5 (es) 2020-07-01
BRPI0414254B1 (pt) 2021-03-02
CN1946382B (zh) 2010-12-08
ES2735216T3 (es) 2019-12-17
IL173737A (en) 2012-04-30
JP5026077B2 (ja) 2012-09-12
US20110136915A1 (en) 2011-06-09
HRP20130114T4 (hr) 2019-12-27
HUE043958T2 (hu) 2019-09-30
PT3395340T (pt) 2019-07-15
TR201910177T4 (tr) 2019-08-21
EP3395338A1 (en) 2018-10-31
IL173737A0 (en) 2006-07-05
TR201909267T4 (tr) 2019-07-22
DK1663182T4 (da) 2020-02-17
EP1663182B2 (en) 2019-11-20
SI3395340T1 (sl) 2019-08-30
EP3395339B1 (en) 2019-04-17
EP3260117B8 (en) 2019-11-27
EP3260117A1 (en) 2017-12-27
BRPI0414254A (pt) 2006-11-07
HUE045411T2 (hu) 2019-12-30
EP3395340A1 (en) 2018-10-31
JP2015007089A (ja) 2015-01-15
ZA200602710B (en) 2007-04-25
EP3395338B1 (en) 2019-05-01
ES2812198T1 (es) 2021-03-16
EP3395340B1 (en) 2019-04-17
DK3260117T3 (da) 2019-07-01
EA013425B1 (ru) 2010-04-30
PT3395339T (pt) 2019-07-15
CY1122259T1 (el) 2020-11-25
CY1121812T1 (el) 2020-07-31
SI2821067T1 (en) 2018-03-30
BRPI0414254B8 (pt) 2021-05-25
HUE044279T2 (hu) 2019-10-28
ES2737348T3 (es) 2020-01-13
EP1663182B1 (en) 2013-01-16
EP3578175A1 (en) 2019-12-11
US20210052518A1 (en) 2021-02-25
EP3395339A1 (en) 2018-10-31
EP3395340B8 (en) 2019-12-11
US20190117592A1 (en) 2019-04-25
SI3260117T1 (sl) 2019-08-30
PL3395340T3 (pl) 2019-10-31
SG146608A1 (en) 2008-10-30
NZ545498A (en) 2010-04-30
HUE044822T2 (hu) 2019-11-28
AU2004279318A1 (en) 2005-04-21
TR201910447T4 (tr) 2019-08-21
BR122018013029B1 (pt) 2022-04-12
PT1663182E (pt) 2013-03-14
CA2536487C (en) 2011-10-25

Similar Documents

Publication Publication Date Title
CY1119609T1 (el) Ταχειας διαλυτοποιησης σκευασμα σινακαλσετης
CY1121877T1 (el) Φαρμακευτικη συνθεση η οποια περιλαμβανει πιμοβενδανη
CY1110019T1 (el) Συνδυασμενη θεραπεια με υποκατεστημενες οξαζολιδινονες
CY1107758T1 (el) Πολυμορφα ενος αναλογου εποθεινολης
CY1111797T1 (el) Τοπικη φαρμακοτεχνικη μορφη ιβερμεκτινης για την θεραπεια δερματολογικων καταστασεων
CY1121125T1 (el) Συνθεσεις για τη θεραπευτικη αντιμετωπιση του πονου και/ή της φλεγμονης
CY1117470T1 (el) Στερεα δοσολογικα σκευασματα με βελτιωμενη ενδοστοματικη προσροφηση
BRPI0418228A (pt) forma de dosagem, e, métodos de tratamento de dor e de episódios de dor incidente de cáncer, e de preparação de um tablete para administração bucal, gengival ou sublingual de fentanil
CY1106478T1 (el) Μεθοδος για την παραγωγη αμορφης επιβραδυντικης μητρας μη διαλυτης στο υδωρ
DK1307227T3 (da) Farmaceutiske sammensætninger
ECSP034826A (es) Método para fabricar una composición farmacéutica de dosis baja
CY1110906T1 (el) Φαρμακευτικη συνθεση για ρινικη χορηγηση φεντανυλης
CY1109013T1 (el) Νεα 4,4΄-διθειοδις-(3-αμινοβουτανιο-1-σουλφονικα) παραγωγα και συνθεσεις που τα περιεχουν
CY1110913T1 (el) Παραγωγα 2-πυρρολιδιν-2-υλο-[1,3,4]-οξαδιαζολης και η χρησιμοποιηση τους σαν αντικαταθλιπτικα
CY1108377T1 (el) Χρηση ενωσεων 1-φαινυλο-3-διμεθυλαμινο-προπανιου για τη θεραπεια της ακρατειας ουρων
DK1387844T3 (da) Retinolderivaters forstærkning af aktive stoffer ved micellær fremstilling
CY1105275T1 (el) Ενωσεις υποκατεστημενης γ-λακτονης ως ανταγωνισται - νμda
TW200509984A (en) Injectable dosage form of flupirtine
CY1113703T1 (el) Ταχειας διαλυσης φαρμακοτεχνικη μορφη της σινακαλσετης hci
CY1105317T1 (el) Χρηση υποκατεστημενων ενωσεων 6-διμεθυλαμινομεθυλο-1-φαινυλο-κυκλοεξανιου για τη θepαπεια της ακρατειας ουρων
CY1105142T1 (el) Χρηση υποκατεστημενων ενωσεων 6-διμεθυλαμινομεθυλο-1-φαινυλο-κυκλοεξανιου για τη θepαπεια της ακρατειας ουρων
CY1106385T1 (el) Χρηση παραγωγων της εποθειλονης για τη θepαπεια του υπepπαραθυρεοειδισμου
BRPI0507985A (pt) derivados de piperazina uréia para o tratamento de endometriose
CR7754A (es) Derivados de 4-piridil-metil-ftalazina para la fabricacion de un medicamento para el tratamiento de sindromes mielodisplasticos
ATA8192003A (de) Verwendung von oxicam-verbindungen